This report summarizes the overall trends in research activity across all three campuses of the University of Michigan through March 31, 2018. Figure 1 shows that total research expenditures through the first nine months of fiscal year 2018 are ahead of the previous year by 4.1 percent. It is important to note that total research expenditures for fiscal year 2017, which closed on June 30, 2017, reached a record high of \$1.48 billion.

The number of research submissions in March was down slightly from March 2017, as shown in Figure 2, but total submissions for the year remain 1.9 percent ahead of our pace from the previous year. Figure 3 shows the value of those submissions is down 16.4 percent year to date compared to the first nine months of fiscal year 2017.

Figures 4 and 5 show the number of new research awards from external sponsors are up 3.2 percent, and their value has increased by 4.2 percent when compared to the previous fiscal year—led by a 3-year, \$3.6 million award to help fund microwave sensor technology.

S. Jack Hu, Vice President for Research

Daryl Weinert, Associate Vice President for Research, Business Operations




Figure 1



U-M Research Award and Expenditures Report

FY 2016: \$1,022,354,392 FY 2017: \$1,086,754,204 FY 2018: \$1,130,864,117

Figure 2

Submissions By Count





Figure 3

Submissions By Amount



FY	2016:	5,306
FY	2017:	5,710
FY	2018:	5,818

FY 2016: \$3,477,023,077 FY 2017: \$4,499,595,993 FY 2018: \$3,763,089,890

FY 2016

Figure 4

Awards By Count






Figure 5


Awards By Amount





FY 2016

FY	2016: 2,618
FY	2017: 2,702
FY	2018: 2,789



FY 2016:	\$1,016,414,821
FY 2017:	\$1,089,269,055
FY 2018:	\$1,134,759,069

Figure 6

For a complete list, visit orsp.umich.edu/saw.

20 Largest Project Awards: March 2018

Wing, Shaomen International Mathematicity Design and development of new anticancer drugs Ascentage Pharma Group Corporation, Lik. SA 48.527 A 30 Avan, Ajail Int Mathematicity Chase III, Randomizad, Double-Billid, Pleceba-Controlled Chase Tarlow March Sharp and Dohme Research S3.406.524 4.0 Smith, Jennifer Epidemiology Chase Tarlow Sa.406.524 4.0 Smith, Jennifer Epidemiology Chase Tarlow Sa.406.524 4.0 Smith, Jennifer Epidemiology Chase Tarlow Sa.406.524 4.0 Smith, Jennifer Epidemiology Chaster Tarlow Sa.406.526 4.0 Keep, Richard Neurosurgery Editational Institutes of Health Sa.406.526 6.0 Maust, Donovan Payoh - Genistric Pational Meath and Human Services, Department Sa.240.535 3.8 Desch, Karl Peidhard Human Services, Department Si.446.400 6.0 Parkology Department The Ode of the PAFC Bubblic CorP3 in normal Health and Human Services, Department Si.134.620 6.0 Parkos, Charles Pathode Human Services, Department Si.134.620	Principal Investigator	Department	Proposal Title	Sponsor	Award Sponsor Total	Estimated Award Duration (years)
Value of the second o	Sarabandi, Kamal	COE EECS - ECE - Rad	Joint Center in Microwave Sensor Technology		\$3,600,000	3.0
Avea, Ajai International probability of the optimization of	Wang, Shaomeng		Design and development of new anticancer drugs	Ascentage Pharma Group Corporation, Ltd.	\$3,418,327	3.0
Altinution Department ^{**} Cardiovascular Risk Factors of-National Institutes of Health 42.07.0.00 2.3 Keeep, Richard Neurosurgery Early hematome lysis and hemoglobin toxicity in frazowarchal hemorthage Health and Human Services, Department \$2.240,535 5.0 Maust, Donovan Psych - Geriatric Patient, Caragiovar, and Regional Drivers of Potentially Perinstal Health and Human Services, Department \$2.240,535 3.8 Desch, Karl Pedintics-Meental/ Perinstal The Molecular Gero Dementia Policy Perinstal Health and Human Services, Department \$1.946,460 4.0 Muntean, Andrew Pathology Department Structure function studies in intestinal epithelial JAM Health and Human Services, Department of National Institutes of Health \$1.946,460 4.0 Muntean, Andrew Pathology Department The role of the PAF's substitic Add Tai normal Health and Human Services, Department of National Institutes of Health \$1.946,460 6.0 Lei, Yu DEN Pariodontics and Oral Med Derviso a Therapeutic Anno-vasccine against Head and drivitational Institutes of Health \$1.946,460 5.0 Init Med Hematology Derviso a Therapeutic Anno-vasccine against Head and drivitational Institutes of Health \$1.940,800 <td>Alva, Ajjai</td> <td></td> <td>Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy</td> <td>Merck Sharp and Donme Research</td> <td>\$3,406,524</td> <td>4.0</td>	Alva, Ajjai		Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy	Merck Sharp and Donme Research	\$3,406,524	4.0
NetPi, Rufnald NetDistry Print Intracembra hemoryhage of-National Institutes of Health S2.002.003 3.0 Maust, Donovan Paych - Gentatric Patient, Caregiver, and Regional Drivers of Potentially Foundation for State Demontale Policy Health and Human Services, Department of-National Institutes of Health S2.240.335 3.8 Desch, Karl Perinatal The Volecular Genetics of Venous Thromboembolic Disease Health and Human Services, Department of-National Institutes of Health \$1,949,167 5.0 Parkos, Charles Pathology Department Structure function studies in intestinal epithelial JAM Health and Human Services, Department of-National Institutes of Health \$1,946,480 4.0 Muntean, Andrew Pathology Department The role of the PAF celabini Cdc/3 in normal Health and Human Services, Department of-National Institutes of Health \$1,946,480 4.0 Muntean, Andrew Pathology Department The role of the PAF celabini Cdc/3 in normal Health and Human Services, Department of National Institutes of Health \$1,946,480 4.0 Ital, Yu DENT Periodontics and Neck Cancer Develop a Therapeutic Nano-vaccine against Head and eAvatonal Institutes of Health Health and Human Services, Department of National Institutes of Health \$1,861,860 \$0.0	Smith, Jennifer			Health and Human Services, Department of-National Institutes of Health	\$2,878,306	3.8
Maiust, Donovan Paych - Geriatric Pack Actional Institutes of Health Perinatal S2,240,535 3.8 Desch, Kart Pediatrics-Neonalal/ Perinatal The Molecular Cene for Dementia Policy Disease Health and Human Services, Department of National Institutes of Health \$1,949,167 5.0 Parkos, Charles Pathology Department Structure function studies in intestinal epithelial JAM Health and Human Services, Department \$1,946,480 4.0 Muntean, Andrew Pathology Department The role of the PAFc subunit Cdc73 in normal Internatopolesis and transformation Health and Human Services, Department \$1,946,480 4.0 Muntean, Andrew Pathology Department The role of the PAFc subunit Cdc73 in normal Internatopolesis and transformation Health and Human Services, Department \$1,946,480 5.0 Talpaz, Moshe Int Med-Hernatology/ Orcology APhase Ib Study of Ruxolithib in Combination with PU-HT1 for the treatment of Subjects with Primary Disclotoms (MCRN) Grant Samus Therapeutics, Inc. \$1,874,518 5.0 Grosh, Kart Mechanical Engineering Active and Nonlinear Models for Cochear Mechanics Health and Human Services, Department of National Institutes of Health \$1,400,000 1.0 Grosh, Kart Mechanical Engineering Acti	Keep, Richard	Neurosurgery			\$2,802,605	5.0
Desch, KahlPerinatalDiseaseof-National Institutes of Health\$1,949,1675.0Parkos, CharlesPathology DepartmentStructure function studies in intestinal epithelial JAMHealth and Human Services, Department of-National Institutes of Health\$1,946,4804.0Muntean, AndrewPathology DepartmentThe role of the PAFc subunit Cdc73 in normal hematopoiesis and transformation of-National Institutes of Health\$1,913,6625.0Lei, YuDENT Periodontics and Oral MedDevelop a Therapeutic Nano-vaccine against Head and Neck CancerHealth and Human Services, Department of-National Institutes of Health\$1,851,9065.0Talpaz, MosheInt Med-Hematology/ OrcologyAPhase Ib Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-P. Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-P. Health and Human Services, Department of-National Institutes of Health\$1,640,0001.0Grosh, KarlMechanical Engineering Active and Nonlinear Models for Cochlear MechanicsMichigan, State of, Economic Development of-National Institutes of Health\$1,193,1082.5Wixom, StellaBusiness Engagement ApplicationMichigan Corporate Relations Network (MCRN) Grant minune checkpoint Inhibitor (CPI) therapy for treatment of.Seattle Genetics, Inc\$1,133,1082.5Lao, ChristopherInt Med-Hematology/ OrnologyPhase Ib dose-ascelation and dose expansion subt/ immune checkpoint Inhibitor (CPI) therapy for treatment of.Seattle Genetics, Inc\$1,133,1082.5Lao, Christoph	Maust, Donovan	Psych - Geriatric	Inappropriate Medical Care for Dementia: Building the		\$2,240,535	3.8
PartNotes, Charles Pathology Department Situation function studies in intestinal epintenia JAM of-National Institutes of Health S1,949,400 4.0 Muntean, Andrew Pathology Department The role of the PAFc subunit Cdc73 in normal hematopolesis and transformation Health and Human Sarvices, Department \$1,913,662 5.0 Lei, Yu DENT Periodontics and Develop a Therapeutic Nano-vaccine against Head and of National Institutes of Health Health and Human Services, Department \$1,851,906 5.0 Talpaz, Moshe Int Med-Hematology/ Oncology APhase Ib Study of Ruxolitinib in Combination with PU-HT1 for the treatment of Subjects with Primary Methonsis (Prost-P., Text-Polytophemia Vara Methopoly) Samus Therapeutics, Inc. \$1,674,518 5.0 Grosh, Karl Mechanical Engineering Active and Nonlinear Models for Cochlear Mechanics Health and Human Services, Department of Polytophemia Vara Methopoly Oncology \$1,400,000 1.0 Alva, Ajjai Int Med-Hematology/ Oncology Aphase 1b dose-escalation and dose-expansion study of Oncology Sature of Ecconomic Development S1,400,000 1.0 Griffin, Brent COE EECS - ECE - Cspl Interactive Learning for Manipulating Piles of Stuff Toyota Research Institute \$1,193,108 2.5 Lao, Christopher Int Med-Hematology/ Oncology APHASE III, OPEN-LABEL, MULTICENTER, TWO-A	Desch, Karl				\$1,949,167	5.0
Multilitatin, Andrew Parilology Department hematopoiesis and transformation of-National Institutes of Health \$1,913,062 5.0 Lei, Yu DENT Periodontics and Oral Med Develop a Therapeutic Nano-vaccine against Head and Neck Cancer Health and Human Services, Department of-National Institutes of Health \$1,851,906 5.0 Talpaz, Moshe Int Med-Hematology/ Oncology APhase Ib Study of Ruxolithib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-P.). Samus Therapeutics, Inc. \$1,674,518 5.0 Grosh, Karl Mechanical Engineering Active and Nonlinear Models for Cochlear Mechanics Center Active and Nonlinear Models for Cochlear Mechanics Corporation Meelth and Human Services, Department on-National Institutes of Health \$1,640,884 5.0 Mixom, Stella Business Engagement Center Michigan Corporate Relations Network (MCRN) Grant Mpelcation Michigan, State of, Economic Development Corporation \$1,400,000 1.0 Alva, Ajjai Int Med-Hematology/ Oncology Aphase 1b dose-escalation and dose-expansion study of immune checkpoint inhibitor (CPI) therapy for treatment of. Seattle Genetics, Inc \$1,339,31 5.1 Griffin, Brent COE EECS - ECE - Cspl Interactive Learning for Manipulating Piles of Stuff <td< td=""><td>Parkos, Charles</td><td>Pathology Department</td><td>Structure function studies in intestinal epithelial JAM</td><td></td><td>\$1,946,480</td><td>4.0</td></td<>	Parkos, Charles	Pathology Department	Structure function studies in intestinal epithelial JAM		\$1,946,480	4.0
Left, TuOral MedNeck Cancerof National Institutes of HealthS1.631,9089.0Talpaz, MosheInt Med-Hernatology/ OncologyPhase Ib Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-P.Samus Therapeutics, Inc.\$1,674,5185.0Grosh, KarlMechanical EngineeringActive and Nonlinear Models for Cochlear MechanicsHealth and Human Services, Department of-National Institutes of Health\$1,540,8845.0Wixom, StellaBusiness Engagement CenterMichigan Corporate Relations Network (MCRN) Grant ApplicationMichigan, State of, Economic Development of National Institutes of Health\$1,400,0001.0Alva, AjjaiInt Med-Hernatology/ OncologyA phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with munue checkpoint inhibitor (CPI) therapy for treatment of.Seattle Genetics, Inc\$1,133,3315.1Griffin, BrentCOE EECS - ECE - CsplInteractive Learning for Manipulating Piles of Stuff RANDOMIZED STUDY OF NOVESTICATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZ.Genentech, Inc.\$1,176,2285.2Tarle, GregoryLSA PhysicsDESI Fiber Positioner Setup - FY17Energy, Department of-Subcontracts\$1,120,1753.0Kim, ChangMary H Weiser Food Allergy CtrAn Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-831 Single Agent in Patients with Metastatic Pancreatic Cancer or Me.Pharmaceutical Research Associates, Inc.\$1,053,4464.9 <td>Muntean, Andrew</td> <td>Pathology Department</td> <td></td> <td></td> <td>\$1,913,662</td> <td>5.0</td>	Muntean, Andrew	Pathology Department			\$1,913,662	5.0
Talpaz, MosheInt Med-Hematology OncologyPU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-P.)Samus Therapeutics, Inc.\$1,674,5185.0Grosh, KarlMechanical EngineeringActive and Nonlinear Models for Cochlear MechanicsHealth and Human Services, Department of-National Institutes of Health\$1,540,8845.0Wixom, StellaBusiness Engagement CenterMichigan Corporate Relations Network (MCRN) Grant ApplicationMichigan, State of, Economic Development Corporation\$1,400,0001.0Alva, AjjaiInt Med-Hematology/ OncologyAphase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASC-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of.Seattle Genetics, Inc\$1,339,3315.1Griffin, BrentCOE EECS - ECE - CsplInteractive Learning for Manipulating Piles of StuffToyota Research Institute\$1,176,2285.2Lao, ChristopherInt Med-Hematology/ OncologyAPHASE III, OPEN-LABEL, MULTICENTER, TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZ.Genentech, Inc.\$1,176,2285.2Tarle, GregoryLSA PhysicsDESI Fiber Positioner Setup - FY17Energy, Department of-Subcontracts\$1,120,1753.0Kim, ChangMary H Weiser Food Homing of Functionally Distinct ILC SubsetsHealth and Human Services, Department of-National Institutes of Health\$1,053,4464.9Crysler, OxanaInt Med-Hematology/ OncologyAn Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerabil	Lei, Yu				\$1,851,906	5.0
Grosh, Kahn Mechanical Engineering Active and Nonlinear Models for Cochlear Mechanics of-National Institutes of Health \$1,940,894 5.0 Wixom, Stella Business Engagement Michigan Corporate Relations Network (MCRN) Grant Application Michigan, State of, Economic Development Corporation \$1,400,000 1.0 Alva, Ajjai Int Med-Hematology/ Oncology Aphase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of. Seattle Genetics, Inc \$1,339,331 5.1 Griffin, Brent COE EECS - ECE - Cspl Interactive Learning for Manipulating Piles of Stuff Toyota Research Institute \$1,193,108 2.5 Lao, Christopher Int Med-Hematology/ Oncology APHASE III, OPEN-LABEL, MULTICENTER, TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZ. Genentech, Inc. \$1,176,228 5.2 Tarle, Gregory LSA Physics DESI Fiber Positioner Setup - FY17 Energy, Department of-Subcontracts \$1,120,175 3.0 Kim, Chang Mary H Weiser Food Allergy Ctr An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-331 Single Agent in Patients with Metastatic Pancreatic Cancer or Me. Pharmaceutical Research Associates, Inc. \$1,053,446 4.9 <td>Talpaz, Moshe</td> <td></td> <td>PU-H71 for the treatment of Subjects with Primary</td> <td>Samus Therapeutics, Inc.</td> <td>\$1,674,518</td> <td>5.0</td>	Talpaz, Moshe		PU-H71 for the treatment of Subjects with Primary	Samus Therapeutics, Inc.	\$1,674,518	5.0
Witcom, Stella Center Application Corporation St.400,000 1.0 Alva, Ajjai Int Med-Hematology/ Oncology A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of Seattle Genetics, Inc \$1,339,331 5.1 Griffin, Brent COE EECS - ECE - Cspl Interactive Learning for Manipulating Piles of Stuff Toyota Research Institute \$1,193,108 2.5 Lao, Christopher Int Med-Hematology/ Oncology A PHASE III, OPEN-LABEL, MULTICENTER, TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZ. Genentech, Inc. \$1,176,228 5.2 Tarle, Gregory LSA Physics DESI Fiber Positioner Setup - FY17 Energy, Department of-Subcontracts \$1,120,175 3.0 Kim, Chang Mary H Weiser Food Allergy Ctr An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or Me Pharmaceutical Research Associates, Inc. \$1,053,446 4.9	Grosh, Karl	Mechanical Engineering	Active and Nonlinear Models for Cochlear Mechanics		\$1,540,884	5.0
Alva, AjjaiInt Med-Hematology/ Oncologyenfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment ofSeattle Genetics, Inc\$1,339,3315.1Griffin, BrentCOE EECS - ECE - CsplInteractive Learning for Manipulating Piles of StuffToyota Research Institute\$1,193,1082.5Lao, ChristopherInt Med-Hematology/ OncologyAPHASE III, OPEN-LABEL, MULTICENTER, TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZGenentech, Inc.\$1,176,2285.2Tarle, GregoryLSA PhysicsDESI Fiber Positioner Setup - FY17Energy, Department of-Subcontracts\$1,120,1753.0Kim, ChangMary H Weiser Food Allergy CtrHoming of Functionally Distinct ILC SubsetsHealth and Human Services, Department of-National Institutes of Health\$1,053,4464.9Crysler, OxanaInt Med-Hematology/ OncologyAn Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or Me.Pharmaceutical Research Associates, Inc.\$1,053,4464.9	Wixom, Stella	00			\$1,400,000	1.0
Lao, ChristopherInt Med-Hematology/ OncologyA PHASE III, OPEN-LABEL, MULTICENTER, TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZGenentech, Inc.\$1,176,2285.2Tarle, GregoryLSA PhysicsDESI Fiber Positioner Setup - FY17Energy, Department of-Subcontracts\$1,162,4252.4Kim, ChangMary H Weiser Food Allergy CtrHoming of Functionally Distinct ILC SubsetsHealth and Human Services, Department of-National Institutes of Health\$1,120,1753.0Crysler, OxanaInt Med-Hematology/ OncologyAn Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or MePharmaceutical Research Associates, Inc.\$1,053,4464.9	Alva, Ajjai		enfortumab vedotin (ASG-22CE) in combination with	Seattle Genetics, Inc	\$1,339,331	5.1
Lao, ChristopherInt Med-Hematology/ OncologyRANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZGenentech, Inc.\$1,176,2285.2Tarle, GregoryLSA PhysicsDESI Fiber Positioner Setup - FY17Energy, Department of-Subcontracts\$1,162,4252.4Kim, ChangMary H Weiser Food Allergy CtrHoming of Functionally Distinct ILC SubsetsHealth and Human Services, Department of-National Institutes of Health\$1,120,1753.0Crysler, OxanaInt Med-Hematology/ OncologyAn Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or MePharmaceutical Research Associates, Inc.\$1,053,4464.9	Griffin, Brent	COE EECS - ECE - Cspl	Interactive Learning for Manipulating Piles of Stuff	Toyota Research Institute	\$1,193,108	2.5
Kim, Chang Mary H Weiser Food Allergy Ctr Homing of Functionally Distinct ILC Subsets Health and Human Services, Department of-National Institutes of Health \$1,120,175 3.0 Crysler, Oxana Int Med-Hematology/ Oncology An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or Me Pharmaceutical Research Associates, Inc. \$1,053,446 4.9	Lao, Christopher		RANDOMIZED STUDY TO INVESTIGATE THE	Genentech, Inc.	\$1,176,228	5.2
Kinn, Chang Allergy Ctr Homing of Punctionally Distinct LC Subsets of-National Institutes of Health \$1,120,175 3.0 Crysler, Oxana Int Med-Hematology/ Oncology An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or Me Pharmaceutical Research Associates, Inc. \$1,053,446 4.9	Tarle, Gregory	LSA Physics	DESI Fiber Positioner Setup - FY17	Energy, Department of-Subcontracts	\$1,162,425	2.4
Crysler, Oxana Int Med-Hematology/ Oncology the Safety, Tolerability, and Activity of TAK-931 Single Pharmaceutical Research Associates, Inc. \$1,053,446 4.9 Agent in Patients with Metastatic Pancreatic Cancer or Me	Kim, Chang		Homing of Functionally Distinct ILC Subsets		\$1,120,175	3.0
Peng, Huei Mcity Honda Leadership Circle Membership with Mcity Honda R & D Americas, Inc. \$999,999 3.0	Crysler, Oxana		the Safety, Tolerability, and Activity of TAK-931 Single	Pharmaceutical Research Associates, Inc.	\$1,053,446	4.9
	Peng, Huei	Mcity	Honda Leadership Circle Membership with Mcity	Honda R & D Americas, Inc.	\$999,999	3.0